In a study screening commercial and experimental CYP51A1 inhibitors for anti-cancer activity, only VFV, a compound with a bulky imidazole-oxadiazole core, showed potent anti-proliferative effects across multiple cancer cell types. This evidence concerns the gene CYP51A1 and cancer.